Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the group has successfully completed Phase 1a monotherapy dose escalation of PD1-Vaxx and will now proceed to combination dose escalation.
The clinical-stage immuno-oncology company is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Chong says it also has appointed industry leaders Ursula McCurry and Dr Nimali Withana to its senior management team.